Ubigene Biosciences

Name: Ubigene Biosciences
Address: Austin, TX, US
Telephone: +18557773210

Home
United States
Austin, TX
Ubigene Biosciences

Make genome editing easier - Your complete solution for cell model engineering | gene-editing services and products

05/29/2026

We know the pain of waiting weeks for a knockout cell line, only to find out the antibody validation failed. 🤦‍♂️💔
Say goodbye to lab heartbreak! Ubigene’s newly upgraded KO Cell Bank offers over 10,000+ KO cell lines, featuring our top-selling, WB-validated stocks for just $2,380!
Why trust Ubigene?
🧬 Fully verified by PCR + Sanger sequencing + Western Blot (Clear band, zero protein expression!).
🚚 Ready-to-ship stocks delivered in 1-2 weeks.
🎓 Academic-exclusive pricing to help stretch your grant budget.
No stock for your target? Our Custom KO Cell Line Service starts at just $1,980!
⏰ Promotion ends July 31, 2026. 👉 Slide into our DMs or click the link in our bio to check your target today!
https://www.ubigene.us/activity/5600?utm_source=facebook&utm_medium=social&utm_campaign=promo_2026&utm_content=wb_validated

05/15/2026

How is CRISPR changing the game for drug discovery? 🧬💉

Identifying a successful drug target used to take decades. Now, with advanced CRISPR screening trends, researchers can scan thousands of genes simultaneously to find the perfect therapeutic match.

In our latest blog post, we explore:
✅ How CRISPR accelerates target validation.
✅ The role of genome-wide screening in personalized medicine.
✅ Why biotech leaders are integrating CRISPR into their early-stage R&D.

At Ubigene, we’re proud to support the scientists making these breakthroughs happen. Explore the trends shaping the future of medicine! 🚀

Read more:
👉 https://www.ubigene.us/application/crispr-screening-drug-discovery-trends?utm_source=instagram&utm_medium=social

05/14/2026

Don’t let bad data ruin a great experiment! 🔍

CRISPR library screening is a powerful tool, but algorithm bias can often skew results, leading researchers down the wrong path.

Our latest technical blog explores the essential steps for robust data analysis in CRISPR Knockout, CRISPRi, and CRISPRa for Cell pools. We break down how to identify systematic errors and which computational tools can help you get the most accurate results from your screening data.

Level up your bioinformatics workflow with Ubigene’s expert insights. 💡

Read more here:
👉 https://www.ubigene.us/application/crispr-library-screening-data-analysis-algorithm-bias?utm_source=facebook&utm_medium=social

05/01/2026

Ever wonder how scientists make CRISPR even more precise? 🧬 It’s all about the "off-switches" and "tuners."

New research is diving deep into AcrIIA27—a protein that helps control gene editing—and how a specific RNA trick (truncation) actually makes the whole system work better. It’s like sharpening the blade of a biological Swiss Army knife. 🔪✨

Check out the latest update from the lab on how we're making gene therapy safer and more efficient.

Details here:
🔗 https://www.ubigene.us/application/acriia27-sgrna-ptp-rna-truncation-enhances-crispr-editing?utm_source=facebook&utm_medium=social

04/30/2026

How close are we to curing genetic diseases? 🧬 The Nature Outlook 2026 is out, and the forecast for gene editing is brighter than ever!

From curing rare blood disorders to tackling complex chronic conditions, the precision medicine revolution is shifting gears. We're seeing faster clinical trials, smarter AI tools, and more lives being changed by CRISPR technology.

Want to know what the next 5 years hold for biotech? Check out our latest breakdown of the Nature report! 👇

Full Story: https://www.ubigene.us/application/nature-outlook-2026-gene-editing-precision-medicine?utm_source=facebook&utm_medium=social

04/25/2026

🔬 New Research: Decoding CRC Tumor Progression

Discover how the m6A-YTHDF1-Notch1 signaling axis maintains cancer cell stemness. This breakthrough identifies YTHDF1 as a key player in promoting Notch1 translation, fueling tumor growth in Colorectal Cancer.

Why it matters:
🔹 Identifies potential therapeutic targets.
🔹 Validates the role of m6A readers in oncology.

🔗 Full article: https://www.ubigene.us/application/m6a-ythdf1-notch1-axis-drives-colorectal-cancer-stemness?utm_source=facebook&utm_medium=social&utm_campaign=crc_m6a_research

04/24/2026

🔬 Optimize Your HTR-8/SVneo Research

As a cornerstone for trophoblast research, HTR-8/SVneo cells require specific handling to ensure reproducible results. From media composition to CRISPR strategies, we've got you covered.

Key takeaways:
✅ How to improve cell viability during transfection.
✅ Avoiding common gene-editing errors in this specific line.

🔗 Explore the protocols: https://www.ubigene.us/application/htr-8-svneo-cell-culture-and-gene-editing-tips?utm_source=facebook&utm_medium=social&utm_campaign=htr8_tips

04/18/2026

Can we turn a tumor’s survival mechanism against itself? 🧬

Researchers have just uncovered a surprising "Achilles' heel" in B-cell acute lymphoblastic leukemia (B-ALL). While many cancers are driven by too much β-catenin, B-ALL cells actually need to keep their β-catenin levels extremely low to stay alive.

By using CRISPR functional genomics, the team found that inhibiting GSK3β forces β-catenin to build up. This buildup recruits a repressive complex that shuts down the MYC gene—effectively killing the leukemia cells.

This discovery opens the door to repurposing GSK3β inhibitors as a powerful, selective treatment for resistant B-ALL.

Dive into the science behind the screen:
🔗 https://www.ubigene.us/application/crispr-screen-gsk3b-b-all-beta-catenin?utm_source=facebook&utm_medium=social

04/17/2026

Why do only 10-30% of cancer patients respond to immunotherapy? 🤔
New research suggests a "metabolic trap" within the tumor might be the culprit!

A team from Southern Medical University has discovered that tumors use a protein called SNX17 to "consume" Uridine in the microenvironment. This leaves CD8+ T cells starving for nutrients, leading to impaired N-glycosylation and exhaustion.

💡 The Good News: Supplementing Uridine acts like "recharging the battery" for T cells, significantly boosting the effectiveness of anti-PD-1 therapies! This low-cost strategy offers a promising new path to overcome ICB resistance.

Discover the full metabolic mechanism here:
🔗 https://www.ubigene.us/application/uridine-snx17-cd45-n-glycosylation-icb-resistance?utm_source=facebook&utm_medium=social

04/10/2026

💡 Struggling with low knock-in efficiency or off-target effects?

A new CRISPR-based strategy — LOTI — is changing how scientists approach gene integration.

It enables:
✅ Precise insertion of large DNA fragments
✅ Reduced off-target mutations
✅ Improved in vivo editing performance

This could be a major step forward for gene therapy and complex genome engineering.

🔍 Explore the full breakdown:
https://www.ubigene.us/application/loti-efficient-precise-gene-integration?utm_source=facebook&utm_medium=social&utm_campaign=loti_article

Address

Austin, TX

Telephone

+18557773210

Website

https://www.ubigene.us/

Alerts

Be the first to know and let us send you an email when Ubigene Biosciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Ubigene Biosciences:

Want your business to be the top-listed Engineering Company in Austin?